| 28th week of 2009 patent applcation highlights part 31 |
| Patent application number | Title | Published |
|---|
| 20090175861 | USE OF A B-CELL-DEPLETING ANTIBODY FOR TREATMENT OF POLYOMA VIRUS INFECTIONS - The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection. | 2009-07-09 |
| 20090175862 | COMBINATION THERAPY EMPLOYING LYMPHOTOXIN BETA RECEPTOR BINDING MOLECULES IN COMBINATION WITH SECOND AGENTS - This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other biologic agents, as well as therapeutic methods. | 2009-07-09 |
| 20090175863 | AGENTS TARGETING CD138 AND USES THEREOF - Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells. | 2009-07-09 |
| 20090175864 | IGF-1 AND IGF-2 CHIMERIC POLYPEPTIDES AND THERAPEUTIC USES THEREOF - Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using the pharmaceutical compositions of the invention are also provided. The diseases or conditions treatable with the methods include muscle atrophy as a result of, for example, aging, cachexia, rheumatoid arthritis, diabetes, disuse or immobilization of muscle, and the like, as well as dwarfism and myocardial infarction. | 2009-07-09 |
| 20090175865 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: | 2009-07-09 |
| 20090175866 | TREATMENT OF B-CELL MALIGNANCIES - The present invention generally relates to a pharmaceutical composition and to an improved method of preventing, attenuating and treating multiple myeloma by administering to an individual in need thereof at least one antibody to fibroblast growth factor receptor 3 (FGFR3). In particular, the at least one FGR3 antibody induces apoptosis of myeloma cells expressing wild type FGFR3. | 2009-07-09 |
| 20090175867 | Single-Chain Multivalent Binding Proteins with Effector Function - Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition. | 2009-07-09 |
| 20090175868 | IGF-IR antagonists as adjuvants for treatment of prostate cancer - The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome. | 2009-07-09 |
| 20090175869 | Pulsatile Dosing of Gossypol for Treatment of Disease - This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 2009-07-09 |
| 20090175870 | YKL-40 MONOCLONAL AUTHORITY - The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40. | 2009-07-09 |
| 20090175871 | METHOD FOR DEMONSTRATING PRESENCE OR ABSENCE OF MARKERS ASSOCIATED WITH THE PRESENCE AND/OR THE CHEMOSENSITIVITY OF TUMORS - A method for detecting presence or absence of a tumor in a mammal and/or its sensitivity to chemotherapies, including, on a biological sample from said mammal, detecting and/or quantifying: presence of an eEF1A1 protein, and/or presence of antibodies directed against an eEF1A1 protein or a fragment including at least one epitope of eEF1a1 protein, and/or presence of a MARK3 protein, and/or presence of antibodies directed against a MARK3 protein or a fragment comprising at least one epitope of the MARK3 protein. | 2009-07-09 |
| 20090175872 | Treatment of Conditions Involving Demyelination - The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrcoyte progenitor cells with an ErbB2 binding agent. | 2009-07-09 |
| 20090175873 | Inhibiting tumor cell invasion, metastasis and angiogenesis - The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion. | 2009-07-09 |
| 20090175874 | NOVEL INTERLEUKIN-1 RECEPTOR INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND BINDING - Novel IL-1-R intracellular ligand proteins are disclosed. Polynucleotides encoding the IL-1-R intracellular ligand protein are also disclosed, along with vectors, host cells, and methods of making the IL-1-R intracellular ligand protein. Pharmaceutical compositions containing the IL-1-R intracellular ligand protein, methods of treating inflammatory conditions, and methods of inhibiting IL-1-R intracellular domain binding are also disclosed. Methods of identifying inhibitors of IL-1-R intracellular domain binding and inhibitors identified by such methods are also disclosed. | 2009-07-09 |
| 20090175875 | Molecules and Methods for Modulating Complement Component - Compositions that bind to C3b epitopes and methods of using the compositions are described herein. | 2009-07-09 |
| 20090175876 | METHODS OF USING PHHLA2 TO CO-STIMULATE T-CELLS - The invention provides pHHLA2 co-receptor polypeptides and functional fragments, antibodies to same, isolated polynucleotides encoding same, vectors containing the polynucleotides, cells containing the vectors. Methods of making and using these co-stimulatory pHHLA2 co-receptors molecules are also disclosed. | 2009-07-09 |
| 20090175877 | METHODS OF INHIBITING METASTASIS - Methods of inhibiting metastasis or maintenance of various cancers are provided. In particular, the method makes use of fact that certain trafficking of cancers depend upon identified proteins, which serve as markers. Additional methods of screening are also provided. | 2009-07-09 |
| 20090175878 | Cerebral Vasospasm Inhibitor - An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient. | 2009-07-09 |
| 20090175879 | NOVEL TARGET IN THE TREATMENT OF CYTOKINE RELEASE SYNDROME - A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection as well as adverse reaction in drug therapy. | 2009-07-09 |
| 20090175880 | ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205) - Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antib | 2009-07-09 |
| 20090175881 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 2009-07-09 |
| 20090175882 | METHODS AND COMPOSITIONS FOR TREATING HYPERALGESIA - This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific inhibitors to treat or alleviate pains mediated by noxious mechanosensation. | 2009-07-09 |
| 20090175883 | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations - The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention. | 2009-07-09 |
| 20090175884 | MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS - Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein, PrP, which has been identified on various cancer cell lineages. | 2009-07-09 |
| 20090175885 | METHOD OF CONTROLLING INSECT PESTS IN COTTON - An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton. | 2009-07-09 |
| 20090175886 | MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES - The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the growth of CD30 cells, such as tumor cells, are also provided. | 2009-07-09 |
| 20090175887 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 2009-07-09 |
| 20090175888 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE - The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides prodrugs and conjugates of the duocarmycin analogues with the linker arms of the invention. | 2009-07-09 |
| 20090175889 | HIV VACCINE - The invention provides a polynucleotide encoding an envelope protein comprising gp120 of human immunodeficiency virus-1 (HIV-1) having a mutation at amino acid residues 197-199 whereby a single N-linked glycan is removed. In a typical embodiment, the mutation replaces the asparagine (N) at residue 197 with another amino acid, such as glutamine (Q), creating an N197Q mutation. Because the N197 glycan is highly conserved among HIV-1 subtypes, this approach is applicable across HIV-1 isolates. The invention provides polypeptides, polynucleotides encoding the polypeptides, vectors, and recombinant viruses containing the polynucleotides, antigen-presenting cells (APCs) presenting the polypeptides, immune cells directed against HIV, and pharmaceutical compositions. The invention additionally provides methods, including methods for preventing and treating infection, for killing infected cells, for inhibiting viral replication, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, and for enhancing production of neutralizing antibody. | 2009-07-09 |
| 20090175890 | USE OF IMMATURE DENDRITIC CELLS TO SILENCE ANTIGEN SPECIFIC CD8+ T CELL FUNCTION - This invention provides methods for silencing a pre-existing immune response in a mammal, as for example, in the setting of autoimmune diseases. The method comprises administering to a mammal immature dendritic cells which have been contacted in vitro with an antigen, or to target the antigen to immature dendritic cells in vivo, in order to silence and/or suppress a pre-existing CD8+ T cell immune response and induce IL-10 producing CD8+ T cells in said mammal. This invention further relates to methods for propagating immature dendritic cells, for maintaining immaturity by modification ex vivo, and uses thereof, including generation of regulatory T cells for passive immunotherapy. The present invention also relates to compositions and kits comprising immature dendritic cells and antigens. | 2009-07-09 |
| 20090175891 | Preventive And Therapeutic Vaccine For Huntington's Disease - A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer's, Parkinson's, Huntington's, Amyloid lateral sclerosis (ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Huntington's in animals and its practicability for therapy in humans. | 2009-07-09 |
| 20090175892 | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 2009-07-09 |
| 20090175893 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinopathy, progressive macular degeneration or rheumatoid arthritis. | 2009-07-09 |
| 20090175894 | METHODS AND MATERIALS FOR PRODUCING A GENERIC ANTI-AMYLOID IMMUNE RESPONSE IN MAMMALS - Compositions containing fibrillar aggregates of amyloidogenic polypeptides and adjuvants are described as well as methods of using such compositions to induce generic anti-amyloid immune responses in mammals. | 2009-07-09 |
| 20090175895 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA - The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by | 2009-07-09 |
| 20090175896 | CAT Allergen Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens. | 2009-07-09 |
| 20090175897 | SYSTEM FOR RAPID PRODUCTION OF HIGH-TITER AND REPLICATION-COMPETENT ADENOVIRUS-FREE RECOMBINANT ADENOVIRUS VECTORS - The present invention relates generally to the fields of gene therapy, immunology, and vaccine technology. More specifically, the invention relates to a novel system that can rapidly generate high titers of adenovirus vectors that are free of replication-competent adenovirus (RCA). Also provided are methods of generating these RCA-free adenoviral vectors, immunogenic or vaccine compositions comprising these RCA-free adenovirus vectors, methods of expressing a heterologous nucleic acid of interest in these adenovirus vectors and methods of eliciting immunogenic responses using these adenovirus vectors. | 2009-07-09 |
| 20090175898 | Influenza Hemagglutinin And Neuraminidase Variants - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2009-07-09 |
| 20090175899 | RECOMBINANT RSV VIRUS EXPRESSION SYSTEMS AND VACCINES - The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV. | 2009-07-09 |
| 20090175900 | METHODS FOR PACKAGING PROPAGATION-DEFECTIVE VESICULAR STOMATITIS VIRUS VECTORS - A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) in a cell culture is provided. The method involves introducing a plasmid vector encoding an optimized VSV G gene into a cell; expressing VSV G protein from the optimized VSV G gene; and introducing a propagation-defective VSV into the cell expressing the VSV G protein encoded by the optimized VSV G gene. The method further includes growing the cells in culture; and recovering the propagation-defective VSV from the culture. | 2009-07-09 |
| 20090175901 | IMMUNOSTIMULATORY RECOMBINANT INTRACELLULAR PATHOGEN IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing Mycobacteria major extracellular proteins and immunostimulatory molecules. | 2009-07-09 |
| 20090175902 | Immunogenic Substances Comprising A Polyinosinic Acid-Polycytidilic Acid Based Adjuvant - The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine) selected from viral, bacterial, fungal, parasitic and/or cancer antigens. The present invention further contemplates methods of use of such adjuvant compositions, particularly in eliciting an immune response, in particular a mucosal immune response to an antigenic compound. | 2009-07-09 |
| 20090175903 | MEASLES SUBUNIT VACCINE - Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for example, in methods for treating or preventing a measles virus infection and eliciting a protective immune response. | 2009-07-09 |
| 20090175904 | Expressing hepatitis B virus surface antigen for vaccine preparation - HBsAg is expressed in a | 2009-07-09 |
| 20090175905 | TRANSFECTION REAGENT AND METHOD FOR ENHANCING TRANSFECTION EFFICIENCY - A transfection reagent and a method for enhancing transfection efficiency are described. A nucleic acid is provided, and a disaccharide is added as a transfection reagent. The disaccharide is composed of two identical monosaccharides. The transfection reagent is then applied to cells to introduce the nucleic acid into the cells. | 2009-07-09 |
| 20090175906 | Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof - The present invention relates to methods for generating genetically modified and attenuated strains of vesicular stomatitis virus (VSV) for use in the preparation of immunogenic compositions. More particularly, the invention relates to the identification of particular genetic modifications of attenuated VSV that result in an increased yield of virus and an increase in stability of the attenuated strains for preparation of the immunogenic compositions. Methods for cell culture propagation and use in large scale production of VSV is also disclosed. | 2009-07-09 |
| 20090175907 | Multi Plasmid System For The Production Of Influenza Virus - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided. | 2009-07-09 |
| 20090175908 | Influenza Hemagglutinin And Neuraminidase Variants - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2009-07-09 |
| 20090175909 | Influenza Hemagglutinin And Neuraminidase Variants - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 2009-07-09 |
| 20090175910 | Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization - Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections. | 2009-07-09 |
| 20090175911 | Bacterial Production of Carotenoids - The present invention is based on a | 2009-07-09 |
| 20090175912 | Haemophilus Influenza Outer Membrane Protein and Use Thereof in Vaccination - This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable | 2009-07-09 |
| 20090175913 | AMMENDOLA/SALMONELLA ENTERICA STRAINS OF REDUCED PATHOGENICITY, METHOD FOR THEIR PREPARATION AND USES THEREOF - The invention concerns novel | 2009-07-09 |
| 20090175914 | Salts or Complexes of Methyl Donors With Phytic Acid or Its Derivatives and Method for the Synthesis Thereof - The invention concerns the production of salts or chelates of methyl donors, in particular S-adenosyl-L-methionine or SAMe and betaine or N,N,N-trimethylglycine, with phytic acid or with phosphorylate inositol, possibly partially salified with metal cations, with the formation of stable, totally natural, compounds having a biological activity typical of the starting methyl donors and also combined with, and enhanced by, the biological activity typical of phytic acid or of inositol. | 2009-07-09 |
| 20090175915 | Nanoparticle Compositions Providing Enhanced Color for Cosmetic Formulations - The present invention relates to cosmetic, dermatological, and pharmaceutical compositions that deliver, in an acceptable vehicle or carrier comprising a film former or wax and an effective amount of nanoparticles and one or more pigments and methods for improving the appearance of a biological surface by altering the optical properties of the biological surface. The compositions of the invention enhance color and may be topically applied to the biological surface in an amount effective in improving the aesthetic and natural appearance of the biological surface. | 2009-07-09 |
| 20090175916 | Sheet-shaped cosmetic product - A sheet-shaped cosmetic product of the invention has a sheet and a stratified cosmetic cake disposed on the sheet with an adhesive layer sandwiched therebetween, and the adhesive layer and the cosmetic cake form a bonding zone in cooperation with each other, the bonding zone in which the adhesive layer and the cosmetic cake are engaged with and bonded to each other. | 2009-07-09 |
| 20090175917 | Tooth Bleaching Agent - The invention relates to “tooth-bleaching agent” compositions and to their applications in whitening teeth. The dental bleaching agent of the present invention comprises apatite, especially preferably in particle sizes in the nano range, likewise especially preferably in the form of fluorapatite. The tooth-bleaching agent can have a desensitising action and a positive action in respect of the remineralisation of the tooth surface. | 2009-07-09 |
| 20090175918 | Ultra-Passivation of Chromium-Containing Alloy and Methods of Producing Same - The invention concerns article having a surface oxide layer up to 20 nm thick, the surface oxide layer comprising chromium and cobalt oxides where the atomic ratio of Cr/Co is more than 3. The invention also concerns methods for treating a chromium containing material, said method comprising contacting said material with a gas plasma under conditions effective to oxidize at least a portion of the material; and contacting said material with an acid. The treated surface is corrosion resistant and can be used in orthopedic implants, especially the wear surface of the orthopedic implant to reduce wear, and other corrosive environment. | 2009-07-09 |
| 20090175919 | CHEMICAL COMPOSITION OF HYDROGELS FOR USE AS ARTICULATING SURFACES - The present invention provides a hydrogel composition comprising at least one polymer with functional groups including alcohol groups, acid groups, and amide groups and where the ratio of the functional alcohol groups to functional acid groups in the hydrogel composition ranges from about 16:1 to about 3:2. The present invention also provides a method of repairing an articulating surface in a body using the inventive composition. The inventive hydrogel composition is created by blending two or more polymers to achieve the desired ratio of functional groups, reacting at least one polymer with a reagent that results in the formation of alcohol, acid, and/or amide functional groups of the desired ratio, and/or polymerizing at least one monomer to achieve the desired ratio of functional groups. | 2009-07-09 |
| 20090175920 | Biomaterial for osteosynthesis - The present invention relates to a biomaterial for the manufacture of osteosynthesis articles with dynamic mechanical properties analogous to calcified tissue, comprising a semi-aromatic polyamide matrix and at least one reinforcing means. | 2009-07-09 |
| 20090175921 | Chain Extenders - The present invention relates to chain extenders, processes for their preparation and their use in the preparation of biocompatible biodegradable polyurethanes and polyurethane ureas for biomedical applications such as stents, scaffolds for tissue engineering. The chain extenders comprise a compound of formula (I) | 2009-07-09 |
| 20090175922 | THREE DIMENSIONAL PURIFIED COLLAGEN MATRICES - Cell culture scaffolds presenting a more biologically relevant microenvironment are disclosed. More particularly, these cell culture scaffolds comprise three-dimensional matrices/biomaterials that are created from solubilized collagen compositions using controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can be used alone or in combination with cells as a tissue graft construct to enhance the repair of damaged or diseased tissues. | 2009-07-09 |
| 20090175923 | HUMANIZED ANTI-AMYLOID BETA ANTIBODIES - Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody. | 2009-07-09 |
| 20090175924 | COATED STENT - A method of implanting a stent whereby the risk of restenosis is reduced, the method including the step of implanting into a patient susceptible to post-implant restenosis a stent coated with a therapeutically effective amount of a compound for reducing the onset or severity of restenosis, the compound containing a high density, negatively charged domain of at least three vicinally oriented phosphorus-containing radicals. | 2009-07-09 |
| 20090175925 | PASSIVE TIME RELEASED SOLUTE TREATMENT - Devices and methods for delivery of a solute to increase blood sugar levels between certain hours in a form that allows for gradual delivery. One variation includes devices and methods for the timed release of a solute of carbohydrate, typically dextrose. | 2009-07-09 |
| 20090175926 | TOPICAL BURN TREATMENT - In some embodiments, a method of reducing the possibility of infection in a burn may include one or more of the following steps: (a) identifying a burn wound, (b) applying topically a molecular sieve agent to the burn wound, and (c) allowing the burn wound to scab over due to absorption of moisture. | 2009-07-09 |
| 20090175927 | Administration of cells and cellular extracts for rejuvenation - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing technologies thereby improving healing and regeneration of all bodily tissues and organs. The present invention relates to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfunction of cells and tissues, and to promote, improve or exceed cellular function in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. Said components can also be synthesized. In other embodiments, the cells are differentiable cells preferably stem cells or eggs. In some embodiments, compositions are used in a method that comprises application of compositions to tissues, including skin and/or wounds after removal of tissue surface layers. In other embodiments, the invention relates to methods of dedifferentiation of cells and/or dedifferentiation followed by differentiation. In other embodiments, the invention relates to managing, preventing, and treating skin diseases. | 2009-07-09 |
| 20090175928 | Lip Plaster - The invention relates to a self-adhesive lip plaster which comprises at least one single-layered matrix and which contains at least one antiviral active medical substance for using in the event of Herpes labialis. Said matrix is arranged on a flexible carrier film which is hydrophobic and also permeable to vapor. | 2009-07-09 |
| 20090175929 | Transdermally absorbable Donepezil Preparation - Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects. | 2009-07-09 |
| 20090175930 | Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball - There is provided a composition comprising an RNA-encapsulated liposome, the RNA comprising a sequence being of 15 to 30 contiguous nucleotides of mRNA of a target gene associated with a disease in an eyeball, and a sequence complementary to the sequence, wherein the liposome is capable of reaching an eyeball, and the like. The liposome in which an RNA is encapsulated is, for example, a liposome composing a complex particle comprising a lead particle and the RNA as constituent components, the lead particle comprising a cationic lipid, and a bilayer lipid membrane for coating the complex particle. The bilayer lipid membrane is a bilayer lipid membrane comprising a neutral lipid, and a lipid derivative, a fatty acid derivative or an aliphatic hydrocarbon derivative of a water-soluble substance as constituent components. | 2009-07-09 |
| 20090175931 | COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS - Factor Xa variants and methods of use thereof are disclosed. | 2009-07-09 |
| 20090175932 | MICELLE ASSEMBLIES - The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R | 2009-07-09 |
| 20090175933 | PREPARATION FOR THE TREATMENT OF DIARRHOEA - A preparation for the treatment of diarrhoea comprising a bulking agent and an anti-diarrhoeal agent wherein the anti-diarrhoeal agent is provided in the form of an anti-motility agent. | 2009-07-09 |
| 20090175934 | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same - Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40% by weight of venlafaxine hydrochloride, about 50 to about 80% by weight of water soluble diluent and about 2 to about 10% of water soluble binder and a coating layer having an effective combination of rate controlling polymers comprising water-soluble polymer and water insoluble, water permeable polymer. | 2009-07-09 |
| 20090175935 | PHARMACEUTICAL COMPOSITIONS OF DULOXETINE - The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat, wherein the enteric coat comprises methacrylic acid copolymer. | 2009-07-09 |
| 20090175936 | Microtablet-Based Pharmaceutical Preparation - A pharmaceutical preparation consisting of various microtablets containing ingredients. The microtablets have the same form and the same weight. | 2009-07-09 |
| 20090175937 | Misuse Preventative, Controlled Release Formulation - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 2009-07-09 |
| 20090175938 | Controlled Release Flurbiprofen and Muscle Relaxant Combinations - This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form. | 2009-07-09 |
| 20090175939 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2009-07-09 |
| 20090175940 | Solubilized ibuprofen - A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium glycinate, potassium glycinate and tribasic sodium and potassium phosphates and mixtures thereof, and reacting the ibuprofen and the first base in essentially dry state. The obtainable granulate and the pharmaceutical compositions and dosage forms that may be produced therefrom are distinguished by their high solubility and rapid disintegration and dissolution in aqueous media, by their good flow properties and compressibility, by rapidly achieving onset of analgesic effect. | 2009-07-09 |
| 20090175941 | Tablet-form slow-release preparation for vertigo - The invention describes a pharmaceutical composition of a slow-release preparation in the form of tablets for the treatment of vertigo of any genesis. A pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down. For this purpose, the pharmaceutical composition additionally contains binding agent, slow-release agent and fillers. | 2009-07-09 |
| 20090175942 | Solid Dosage Form of Olmesartan Medoxomil And Amlodipine - The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof. | 2009-07-09 |
| 20090175943 | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines - The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc. | 2009-07-09 |
| 20090175944 | Gel suitable for implantation and delivery system - The invention concerns a dried form of a porous polymer gel material which may be rehydrated and placed under pressure or compression to induce salvation, thereby forming a high concentration gel, in the form of an injectable viscous putty or dough, which may be implantated in the body. | 2009-07-09 |
| 20090175945 | Systems, Methods, and Formulations for Topically Treating Nail Fungal Infections and Nail Psoriasis - The present invention is drawn to systems, methods, and formulations for treating nail disorders. The system comprises an active agent formulation and a first barrier film. The active agent formulation includes an active agent and an aqueous liquid component. The first barrier film is configured to form a sheath over at least a portion of a finger or toe on which the nail is located. An optional second barrier film, with lower moisture vapor transmission rate than the first barrier film, is placed between the first barrier film and the active agent formulation (or between the active agent formulation and the external environment) to reduce the water evaporation from the active agent formulation. The sheath is configured to be capable of securing and retaining the active agent formulation within the sheath on a finger nail or toe nail while reducing evaporation of the liquid component of the aqueous liquid component of the active agent formulation. The active agent formulation can be a “slow-molding” hydrogel formulation that can slowly flow into the exact shape of the diseased nail to assure intimate contact and continuous delivery of the drug, while cannot be squeezed out of the position during the application. | 2009-07-09 |
| 20090175946 | USE OF GELATIN AND A CROSS-LINKING AGENT FOR PRODUCING CROSS-LINKING MEDICAL GLUES - The invention relates to the use of gelatin and a cross-linking agent to provide a medical glue which forms a cross-linked gelatin gel in an area of application of the human or animal body. According to the invention, (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking medical glue which is then administered to the area of application; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the area of application while forming the cross-linking medical glue. | 2009-07-09 |
| 20090175947 | PHARMACEUTICAL COMPOSITION FOR INJECTIONAL PARTICULARLY TARGETED LOCAL ADMINISTRATION - The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH | 2009-07-09 |
| 20090175948 | AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTI-MICROBIAL AGENT - A method of forming and resulting nano-structured composite includes atomizing a mixture of an amount of each of aminopropyltriethoxysilane, AgNO | 2009-07-09 |
| 20090175949 | MICROPARTICLES FOR DELIVERY TO CELLS AND/OR TISSUES - Delivery of bioactive molecules (BAMs) to organelles, cells, tissues, or animals with high efficiency is desirable. Novel compositions for highly efficient delivery of bioactive molecules by biolistic methods are described. The novel compositions include novel microparticle cores, microparticle core/BAM complexes, microparticle core/nanoparticle complexes and multilayer-microparticle core/BAM complexes. Any one of these may be further modified to include targeting agents. | 2009-07-09 |
| 20090175950 | PHARMACEUTICAL SAFETY DOSAGE FORMS - Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided. | 2009-07-09 |
| 20090175951 | NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS - Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions. | 2009-07-09 |
| 20090175952 | Cefuroxime axetil granule and process for the preparation thereof - A cefuroxime axetil granule composition comprising a non-crystalline cefuroxime axetil solid dispersion or a substantially amorphous cefuroxime axetil, sucrose fatty acid ester, methacrylic acid-ethylacrylate copolymer and a disintegrating agent has highly desirable performance characteristics in terms of masking the bitterness of cefuroxime axetil, as well as high bioavailability and stability of cefuroxime axetil, and thus, can be advantageously used for oral administration of cefuroxime axetil. | 2009-07-09 |
| 20090175953 | Nanodispersions - The invention provides process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of: (i) providing a single phase mixture of: a) a solvent or a mixture of miscible solvents, b) at least one carrier material soluble in solvent (a), said carrier material being also contra-soluble to payload material (c) and solid at ambient temperature, c) at least one a payload material which is soluble in solvent (a), and, (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles. | 2009-07-09 |
| 20090175954 | Sheet-like composition - A sheet-shaped composition is provided which has an improved preservability and handling readiness, as well as a high flexibility in use. Amnion with trehalose added thereto is utilized. Addition of trehalose improves the flexibility of the amnion, and prevents basal membrane and stratum compactum from being damaged during lyophilization process. | 2009-07-09 |
| 20090175955 | HYDROPEROXYLAPATITE AND COMPOSITIONS THEREOF - This invention relates to a compound of general formula Ca | 2009-07-09 |
| 20090175956 | METHOD OF PREPARATION AND COMPOSITION OF ANTIMICROBIAL ICE - Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided. | 2009-07-09 |
| 20090175957 | ACIDIC COMPOSITION - A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminium, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process. | 2009-07-09 |
| 20090175958 | Methods for Deactivating Allergens and Preventing Disease - This invention relates to articles of manufacture containing liquid compositions of hypohalous acid or hypohalous acid salt for deactivating allergens and preventing diseases on hard surfaces, soft surfaces and in the air. The articles of manufacture contain usage instructions with health claims. This invention also includes methods of instructing the public and promoting the use of these compositions. | 2009-07-09 |
| 20090175959 | Controlled Release Solid Preparation - The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an immediate-release part containing a compound unstable to acid and a basic substance, and (3) a sustained-release part containing a compound unstable to acid and a pH-independent material in combination. | 2009-07-09 |
| 20090175960 | Process for Producing Carbon Dioxide Solution, Production Apparatus, And Carbonated Water - A first aqueous solution filled in an electrolytic cell ( | 2009-07-09 |
